Li Xuan1, Xinmiao Jiang, Jing Sun, Yu Zhang, Fen Huang, Zhiping Fan, Xutao Guo, Min Dai, Can Liu, Guopan Yu, Xian Zhang, Meiqing Wu, Xiaojun Huang, Qifa Liu. 1. 1 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. 2 Institute of Hematology, Peking University People's Hospital, Beijing, China. 3 Address correspondence to: Qifa Liu, Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China and Xiaojun Huang, Institute of Hematology, Peking University People's Hospital, Beijing 100044, China.
Abstract
BACKGROUND: Epstein-Barr virus (EBV) infection may result in a spectrum of diseases in recipients of transplant. The aim of this study is to investigate the incidence, clinical characteristics, and prognosis of the spectrum of EBV-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT). METHODS: A total of 263 recipients undergoing allo-HSCT were prospectively enrolled. The blood EBV-DNA loads were regularly monitored by quantitative real-time polymerase chain reaction. RESULTS: The 3-year cumulative incidence of total EBV-associated diseases, posttransplantation lymphoproliferative diseases (PTLD), EBV fever, and EBV end-organ diseases (pneumonia, encephalitis/myelitis, and hepatitis) were 15.6%±2.5%, 9.9%±2.0%, 3.3%±1.3%, and 3.3%±1.2% (2.2%±1.0%, 1.6%±0.8%, and 0.9%±0.6%), respectively. Fever was the most common symptom of EBV-associated diseases. Patients with PTLD had better response rate to rituximab-based treatments compared with those with EBV end-organ diseases (including PTLD accompanied by EBV end-organ diseases) (P=0.014). The 3-year overall survival was 37.3%±13.7%, 100.0%, and 0.0%±0.0% in patients with PTLD, EBV fever, and EBV end-organ diseases (P=0.001). CONCLUSIONS: EBV-associated diseases other than PTLD are not rare in the recipients of allo-HSCT. The clinical manifestations of EBV end-organ diseases are similar to PTLD. EBV end-organ diseases had poorer response to rituximab-based therapy compared with PTLD.
BACKGROUND:Epstein-Barr virus (EBV) infection may result in a spectrum of diseases in recipients of transplant. The aim of this study is to investigate the incidence, clinical characteristics, and prognosis of the spectrum of EBV-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation (allo-HSCT). METHODS: A total of 263 recipients undergoing allo-HSCT were prospectively enrolled. The blood EBV-DNA loads were regularly monitored by quantitative real-time polymerase chain reaction. RESULTS: The 3-year cumulative incidence of total EBV-associated diseases, posttransplantation lymphoproliferative diseases (PTLD), EBV fever, and EBV end-organ diseases (pneumonia, encephalitis/myelitis, and hepatitis) were 15.6%±2.5%, 9.9%±2.0%, 3.3%±1.3%, and 3.3%±1.2% (2.2%±1.0%, 1.6%±0.8%, and 0.9%±0.6%), respectively. Fever was the most common symptom of EBV-associated diseases. Patients with PTLD had better response rate to rituximab-based treatments compared with those with EBV end-organ diseases (including PTLD accompanied by EBV end-organ diseases) (P=0.014). The 3-year overall survival was 37.3%±13.7%, 100.0%, and 0.0%±0.0% in patients with PTLD, EBV fever, and EBV end-organ diseases (P=0.001). CONCLUSIONS:EBV-associated diseases other than PTLD are not rare in the recipients of allo-HSCT. The clinical manifestations of EBV end-organ diseases are similar to PTLD. EBV end-organ diseases had poorer response to rituximab-based therapy compared with PTLD.
Authors: M Wu; J Sun; Y Zhang; F Huang; H Zhou; Z Fan; L Xuan; G Yu; X Guo; M Dai; R Feng; Q Liu Journal: Bone Marrow Transplant Date: 2015-11-23 Impact factor: 5.483
Authors: Stephen J Gurczynski; Megan C Procario; David N O'Dwyer; Carol A Wilke; Bethany B Moore Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-07-22 Impact factor: 5.464
Authors: Jan Styczynski; Walter van der Velden; Christopher P Fox; Dan Engelhard; Rafael de la Camara; Catherine Cordonnier; Per Ljungman Journal: Haematologica Date: 2016-07 Impact factor: 9.941
Authors: M R Wilson; L L Zimmermann; E D Crawford; H A Sample; P R Soni; A N Baker; L M Khan; J L DeRisi Journal: Am J Transplant Date: 2016-10-21 Impact factor: 8.086